These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36548732)

  • 1. Subchronic Oral Cylindrospermopsin Exposure Alters the Host Gut Microbiome and Is Associated with Progressive Hepatic Inflammation, Stellate Cell Activation, and Mild Fibrosis in a Preclinical Study.
    Saha P; Upright M; Bose D; Roy S; Trivedi A; More M; Scott GI; Brooks BW; Chatterjee S
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
    Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
    BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gut-liver axis in immune remodeling of hepatic cirrhosis.
    Guan H; Zhang X; Kuang M; Yu J
    Front Immunol; 2022; 13():946628. PubMed ID: 37408838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.
    Chen D; Le TH; Shahidipour H; Read SA; Ahlenstiel G
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Western diet-induced mouse model of non-alcoholic fatty liver disease associated with metabolic outcomes: Features of gut microbiome-liver-adipose tissue axis.
    Romualdo GR; Valente LC; Sprocatti AC; Bacil GP; de Souza IP; Rodrigues J; Rodrigues MAM; Vinken M; Cogliati B; Barbisan LF
    Nutrition; 2022; 103-104():111836. PubMed ID: 36202025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Gut Microbiome and Hepatocellular Carcinoma.
    Akkız H
    J Gastrointest Cancer; 2021 Dec; 52(4):1314-1319. PubMed ID: 34870783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
    Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma.
    Wright JH; Johnson MM; Shimizu-Albergine M; Bauer RL; Hayes BJ; Surapisitchat J; Hudkins KL; Riehle KJ; Johnson SC; Yeh MM; Bammler TK; Beyer RP; Gilbertson DG; Alpers CE; Fausto N; Campbell JS
    Int J Cancer; 2014 Feb; 134(4):778-88. PubMed ID: 23929039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
    Carter JK; Bhattacharya D; Borgerding JN; Fiel MI; Faith JJ; Friedman SL
    PLoS One; 2021; 16(1):e0244763. PubMed ID: 33395434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies.
    Hodges JK; Sasaki GY; Bruno RS
    J Nutr Biochem; 2020 Nov; 85():108478. PubMed ID: 32801031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophages in the pathophysiology of NAFLD: The role of sex differences.
    Ministrini S; Montecucco F; Sahebkar A; Carbone F
    Eur J Clin Invest; 2020 Jun; 50(6):e13236. PubMed ID: 32294235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of microbiome in patients with decompensated cirrhosis.
    Oikonomou T; Papatheodoridis GV; Samarkos M; Goulis I; Cholongitas E
    World J Gastroenterol; 2018 Sep; 24(34):3813-3820. PubMed ID: 30228776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment.
    Schneider KM; Mohs A; Gui W; Galvez EJC; Candels LS; Hoenicke L; Muthukumarasamy U; Holland CH; Elfers C; Kilic K; Schneider CV; Schierwagen R; Strnad P; Wirtz TH; Marschall HU; Latz E; Lelouvier B; Saez-Rodriguez J; de Vos W; Strowig T; Trebicka J; Trautwein C
    Nat Commun; 2022 Jul; 13(1):3964. PubMed ID: 35803930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.